Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Synthekine is an engineered cytokine therapeutics company dedicated to developing transformative medicines for cancer and autoimmune diseases. By leveraging their expertise in protein engineering and immunology, Synthekine designs and creates cytokine-based therapies that are precisely targeted to specific immune cell subsets. This approach aims to maximize therapeutic benefit while minimizing the off-target toxicities often associated with conventional cytokine treatments. Their pipeline includes innovative candidates designed to modulate the immune system with high selectivity and potency, offering new hope for patients with unmet medical needs.
The headquarters serves as the central hub for Synthekine's research and development, laboratory operations, clinical development, corporate administration, and strategic planning.
The facility likely houses state-of-the-art laboratories for protein engineering, cell biology, immunology research, and process development, designed to foster collaboration and innovation.
As a research-driven biotech company, the work culture is expected to be innovative, collaborative, scientifically rigorous, and fast-paced, with a strong emphasis on translational science and patient impact.
Located in a prominent biotechnology cluster, the South San Francisco headquarters provides access to a rich ecosystem of talent, research institutions, collaborators, and venture capital, crucial for a company in the life sciences sector.
Currently, Synthekine's operational presence is primarily concentrated in the United States, with its research, development, and corporate functions based in South San Francisco. Their global reach is mainly through scientific collaborations, participation in international conferences, and potentially future clinical trial sites as their programs advance. They may engage with international partners for specific research or manufacturing activities.
1618 Station Pkwy NW
South San Francisco
CA
USA
Address: 1618 Station Pkwy NW, South San Francisco, CA 94080
Serves as the nerve center for all company activities, leveraging the Bay Area's rich biotech ecosystem.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Synthekine' leadership includes:
Synthekine has been backed by several prominent investors over the years, including:
Synthekine has made key appointments to strengthen its leadership team over the past year, notably adding a Chief Business Officer. No significant high-profile executive departures have been publicly announced in this period.
Discover the tools Synthekine uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Synthekine likely utilizes common corporate email formats. Based on industry standards and executive team names, the most probable format is firstinitiallast@synthekine.com or first.last@synthekine.com.
flast@synthekine.com (e.g., jdoe@synthekine.com) or first.last@synthekine.com (e.g. jane.doe@synthekine.com)
Format
dray@synthekine.com
Example
80%
Success rate
Synthekine Press Release • November 6, 2023
Synthekine presented promising preclinical data for STK-009 in combination with survodutide, showing potential benefits in treating metabolic dysfunction-associated steatohepatitis (MASH)....more
Synthekine Press Release • October 2, 2023
Synthekine announced the appointment of Stephen E. Abel as its Chief Business Officer, bringing extensive experience in biotech business development and corporate strategy....more
Synthekine Press Release • June 5, 2023
Dr. Naiyer Rizvi, a renowned oncologist and immunotherapy expert, was appointed as Synthekine's Chief Medical Officer to lead the company's clinical development strategy and operations....more
Synthekine Press Release • May 1, 2023
Synthekine secured $100 million in a Series C financing round, co-led by new and existing investors, to advance its pipeline of engineered cytokine therapeutics. Pablo Cagnoni, M.D., was also appointed as Executive Chairman of the Board....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Synthekine, are just a search away.